Therapy with all-trans retinoic acid (ATRA) achieves com plete remission in a high proportion of patients with acute promyelocytic leukemia (APL), but the efficacy is reported to relate to plasma ATRA level after oral administration. The pharmacokinetics of ATRA and 4 oxo all-trans retinoic acid (4-oxo ATRA), a metabolite of ATRA, were studied in four children with APL at the time of initial oral administra tion. After administration of ATRA at a dose of 30mg/m2, the peak plasma ATRA level was 20-741ng/ml and was reached at 60-120min. The patient with the lowest peak plasma level did not achieve complete remission and had a very high 4-oxo ATRA level compared to the patients with complete remission. These findings suggest that accelerated metabo lism of ATRA plays a role in the failure of this agent in the patients without remission.
for ATRA therapy. However, subsequent reports have shown the development of resistance to ATRA and/or leukemic relapse after a relatively short period with accelerated ATRA metabolism may be involved (4) . Accordingly, we investigated plasma levels of 4-oxo ATRA (a metabolite of ATRA) and the pharmacokinetics of ATRA during the treatment of APL to assess the influence of heightened metabolism on the response to therapy. 
Discussion
Although ATRA induces complete remission in a high proportion of APL patients, the duration of remission in patients with APL treated solely with ATRA has been relatively brief. Acquired resistance to ATRA may result from not only genetic or epigenetic causes, but also clinical pharmacological causes (4). Continu ous treatment with ATRA induces a marked decrease in plasma ATRA level (7, 8) . Muindi et al. (9) have shown that pharmacokinetic studies of APL patients who relapsed revealed a significant decrease in plasma ATRA levels compared to the first day of ATRA therapy. These facts suggests that low plasma ATRA levels may be involved in the development of acquired resistance to ATRA. ATRA is metabolized in vivo to produce 4-oxo ATRA, 4-oxo 13-cis retinoic acid (10) and many other isomers, including 9-cis retinoic acid, 9,13-dicis retinoic acid and 13-cis retinoic acid (11) . Then, retinoids are excreted in glucuronised form in the bile. The decreased plasma level of ATRA indicates up-regulation of ATRA metabolism in patients receiving continuous therapy. It has been suggested that the increased metabolism is mediated by cytochrome P-450 oxidation (12) , increased expression of cellular retinoic acid-binding proteins (13) , and increased glucuronidation for excretion in the bile, with down-regulation of gastrointestinal absorption also being postulated (14) . The accelerated metabolism of ATRA may explain the low plasma ATRA levels and the failure to achieve effective ATRA intracellular levels.
In our pediatric APL patients who received ATRA therapy, a substantial level of 4-oxo ATRA was detected in the plasma. It is noteworthy that in the patient without remission, a very low plasma ATRA level was documented in association with a far higher 4-oxo ATRA level than in the patients with remission. This indicates that the lack of remission may have been due to failure to achieve an effective plasma level in this patient, because of enhanced metabolism of ATRA as evidenced by the extremely elevated 4-oxo ATRA level. In this patient, the initiation of ATRA therapy may accelerate the ATRA metabolism of the second therapy.
Many factors may influence the pharmacokinetic behavior of oral administra tion of ATRA, including gastrointestinal absorption and ATRA metabolism (15) . Further studies are needed to clarify the metabolism of ATRA. However, we conclude that it is useful to monitor the plasma concentration of ATRA and its metabolites in order to achieve an appropriate treatment regimen.
